<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121116">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02036671</url>
  </required_header>
  <id_info>
    <org_study_id>VAP-0001</org_study_id>
    <nct_id>NCT02036671</nct_id>
  </id_info>
  <brief_title>Novel Endovascular Access Trial (NEAT)</brief_title>
  <acronym>NEAT</acronym>
  <official_title>Novel Endovascular Access Trial (NEAT): A Study of the FLEX System for Percutaneous AV Fistula Creation in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TVA Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TVA Medical Inc.</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to characterize the safety and efficacy of the FLEX System
      when used to create an arteriovenous fistula (AVF or AV fistula) percutaneously in patients
      with Chronic Kidney Disease (CKD) who require hemodialysis vascular access.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12 month multi-center non-randomized open label investigational study to
      characterize the safety and efficacy of the FLEX system to create an endovascular AVF in
      patients with CKD who require hemodialysis vascular access.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The number of participants who experience device or procedure-related adverse events</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Fistula (Efficacy): The percentage of AV fistulas that can provide prescribed hemodialysis over a 4 consecutive week period.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>EndoAVF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The FLEX System will be used to percutaneously  create a fistula in CKD patients who require hemodialysis vascular access</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The FLEX System will be used to percutaneously  create a fistula in CKD patients who require hemodialysis vascular access</intervention_name>
    <arm_group_label>EndoAVF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for a native surgical arteriovenous fistula, as determined by the treating
             physician.

          -  Adult (age &gt;18 years old).

          -  Established, non-reversible kidney failure requiring hemodialysis.

          -  Written informed consent obtained.

        Exclusion Criteria:

          -  Functioning surgical access in the planned treatment arm.

          -  Pregnant women.

          -  New York Heart Association (NYHA) class III or IV heart failure.

          -  Allergy to contrast dye.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charmaine Lok, MD, MSC, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Toronto General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie E Lynch, PhD</last_name>
    <phone>952-221-2468</phone>
    <email>laurie.lynch@visi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedeh Kiaii, MD, FRCP(C)</last_name>
      <phone>604-681-7191</phone>
      <email>mkiaii@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Mercedeh Kiaii, MD, FRCP(C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmaine Lok, MD</last_name>
      <phone>416-340-4140</phone>
      <email>charmaine.lok@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Charmaine Lok, MD, MSC, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arteriovenous fistula</keyword>
  <keyword>Fistula</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Percutaneous</keyword>
  <keyword>Kidney Disease</keyword>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>CKD</keyword>
  <keyword>hemodialysis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
